<DOC>
	<DOC>NCT01223911</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0000 in subjects with rheumatoid arthritis (RA).</brief_summary>
	<brief_title>A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>CZ: Age between 18 and 65 years (both inclusive) A diagnosis of rheumatoid arthritis of at least three months before entry in trial Active rheumatoid arthritis (RA) Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before trial drug administration Known or suspected allergy to trial product or related products Body mass index (BMI) less than 18.0 or more than 38.0 kg/m2 (inclusive)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>